Why Incyte’s povorcitinib 54-week results matter for hidradenitis suppurativa treatment
Incyte’s povorcitinib reaches 71.4% HiSCR50 at 54 weeks in HS. Analysis of what the STOP-HS data mean for the JAK1 class and the treatment landscape.
Can Incyte’s 54-week povorcitinib data redefine the oral treatment landscape in hidradenitis suppurativa?
Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.
Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.